v3.26.1
Organization, Description of Business and Summary of Significant Accounting Policies - Schedule of Biopharmaceutical and Other Revenues (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Disaggregation of Revenue [Line Items]        
Total revenue $ 150,321 $ 130,164 $ 289,392 $ 244,637
Biopharmaceutical and other revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 802 4,303 1,103 7,887
Biopharmaceutical revenue        
Disaggregation of Revenue [Line Items]        
Total revenue 802 2,630 1,103 4,927
Contract manufacturing and testing        
Disaggregation of Revenue [Line Items]        
Total revenue $ 0 $ 1,673 $ 0 $ 2,960